|本期目录/Table of Contents|

[1]陈永强,许建华,许双塔,等.GATA3在不同分子分型乳腺癌组织中的表达及与预后关系[J].福建医科大学学报,2020,54(04):230-234.
 CHEN Yongqiang,XU Jianhua,XU Shuangta,et al.The Expression of GATA3 in Breast Cancer Tissues with Different Molecular Types and its Correlationship with Prognosis[J].Journal of Fujian Medical University,2020,54(04):230-234.
点击复制

GATA3在不同分子分型乳腺癌组织中的表达及与预后关系(PDF)
分享到:

《福建医科大学学报》[ISSN:1672-4194/CN:35-1192/R]

卷:
第54卷
期数:
2020年04期
页码:
230-234
栏目:
临床研究
出版日期:
2020-09-10

文章信息/Info

Title:
The Expression of GATA3 in Breast Cancer Tissues with Different Molecular Types and its Correlationship with Prognosis
文章编号:
1672-4194(2020)04-0230-05
作者:
陈永强 许建华 许双塔 邱成志 颜长江 吴飞敬
福建医科大学 附属第二医院甲状腺乳腺外科,泉州362000
Author(s):
CHEN Yongqiang XU Jianhua XU Shuangta QIU Chengzhi YAN Changjiang WU Feijing
Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China
关键词:
DNA结合蛋白质类 乳腺肿瘤 受体 雄激素 预后
Keywords:
DNA-binding proteins breast neoplasms receptors androgen prognosis
分类号:
R341; R737.9
DOI:
-
文献标志码:
A
摘要:
目的研究GATA结合蛋白3(GATA3)在乳腺癌组织中的表达与临床病理指标的关系,探讨 GATA3在乳腺癌不同亚型中的表达及预后意义。方法回顾性分析209例乳腺癌患者的临床病理资料。采用免疫组织化学法检测GATA3、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(Her-2)、雄激素受体(AR)、Ki-67增殖指数的表达,采用χ2检验分析GATA3在乳腺癌不同亚型中的表达,采用Kaplan-Meier法进行生存资料分析。结果GATA3的低表达与肿瘤低分化、淋巴结转移、TNM分期等指标相关(P<0.05)。乳腺癌组织中GATA3表达与ER,PR,AR表达呈正相关,与Ki-67增殖指数呈负相关(P<0.05)。GATA3在三阴性乳腺癌中表达率(17.5%)低于非三阴性乳腺癌中表达率(71.0%)(P<0.05); GATA3在Luminal A型、Luminal B型、Her-2过表达型、三阴性乳腺癌组织中表达率分别为89.8%,79.1%,43.4%及17.5%(P<0.05)。在 Luminal型乳腺癌不同临床分期中,GATA3(+)组患者的无病生存期较GATA3(-)患者更长(P<0.05)。结论 GATA3表达与乳腺癌分子分型有关,且参与乳腺癌的发展、转移,可作为判断预后的辅助指标。
Abstract:
ObjectiveTo investigate the correlationship between the expression of GATA binding protein 3(GATA3)and clinicopathological parameters in breast neoplasms, and to further explore the expression of GATA3 in breast cancer tissues with different molecular types and its prognostic significance.MethodsThe clinicopathological data of 209 patients with breast cancer were analyzed retrospectively.The expression of GATA3, ER, PR, Her-2, AR and Ki-67 were evaluated by immunohistochemical staining assays.The expression of GATA3 in different molecular types of breast neoplasms were then assessed using the Chi-square test.The Kaplan-Meier method was used for the analysis of survival. ResultsLow expression of GATA3 in breast cancer tissues was associated with low tumor differentiation, lymph node involvement, late TNM staging(P<0.05).There was a positive correlation between GATA3 expression and ER, PR and AR expression in breast cancer tissues.There was a negative correlation with Ki-67 proliferation index, and the differences were statistically significant(P<0.05).The expression rate of GATA3 in triple negative breast cancer(17.5%)was lower than that in non-triple negative breast cancer(71.0%)(P<0.05).The expression rates of GATA3 in Luminal A, Luminal B, Her-2 overexpression and triple negative breast cancer tissues were 89.8%, 79.1%, 43.4% and 17.5%, respectively.In different clinical stages of Luminal breast cancer, the disease-free survival time of patients in GATA3(+)group was significantly longer than that in GATA3(-)group(all P<0.05).ConclusionThe expression of GATA3 is related to the molecular typing of breast neoplasms and involves in the development and metastasis of breast cancer, which can be used as an auxiliary index to predict the prognosis.

参考文献/References:

[1]Paul S,Home P,Bhattacharya B,et al. GATA factors: Master regulators of gene expression in trophoblast progenitors[J]. Placenta,2017,60(1):61-66.
[2]谢轶群,施俊义,李曦洲,等. GATA3与乳腺癌发生发展关系的研究进展[J]. 第二军医大学学报,2010,31(7):787-789.
[3]张继君,陶丽丽,赵夫娟,等. FOXA1、GATA-3与ER在乳腺癌中的表达及预后意义[J]. 暨南大学学报(自然科学与医学版),2019,40(3):225-233.
[4]黄邦杏,郭学兵,潘华雄,等. 滋养组织中转录因子GATA3的表达及意义[J]. 临床与实验病理学杂志,2016,32(6): 652-655.
[5]傅静,刘裔莎,步宏. 美国临床肿瘤学会/美国病理医师学院乳腺癌雌、孕激素受体免疫组织化学检测指南简介[J]. 中华病理学杂志,2010,39(11):785-786.
[6]Wolff A C,Hammond M E H,Hicks D G,et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update[J]. Archives of Pathology & Laboratory Medicine,2013, 31(31):3997-4013.
[7]Wei L,Zhang T,Guo L,et al. Lysyl hydroxylases are transcription targets for GATA3 driving lung cancer cell metastasis[J]. Scientific Reports,2018,8(1):11905.
[8]Takaku M,Grimm S A,Roberts J D,et al. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network[J]. Nature Communications,2018,9(1):1059.
[9]Fararjeh A S, Tu S H, Chen L C,et al. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer[J]. Human Pathology,2018,80(10):219-230.)
[10]Yawen G,Pan Y,Zeming L,et al. Prognostic and clinicopathological value of GATA binding protein 3 in breast cancer: A systematic review and meta-analysis[J]. PLoS One,2017,12(4):e0174843.
[11]Gulbahce H E,Sweeney C,Surowiecka M,et al. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3 positive tumors[J]. Human Pathology,2013,44(11):2427-2431.
[12]吴小凤,张艳华,岳福军,等. 乳腺癌组织中GATA3的表达及其在乳腺癌发生中的意义[J]. 检验医学与临床,2016, 13(14):1919-1921.
[13]谢轶群,裔海鹰,施俊义,等. GATA3在乳腺癌中的表达及其与预后的关系[J]. 中国癌症杂志,2010,20(12):911-914.
[14]Lee J Y,Park Y J,Oh N,et al. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells[J]. Oncotarget,2017,8(26):42752-42760.
[15]Kouros M H,Slorach E M,Sternlicht M D,et al. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland[J]. Cell,2006,127:1041-1055.
[16]Eeckhoute J,Keeton E K,Lupien M,et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer[J]. Cancer Res,2007,67:6477-6483.
[17]Fararjeh A S,Tu S H,Chen L C,et al. The impact of the effectiveness of GATA3 as a prognostic factor in breast cancer[J]. Human Pathology,2018,80(10):219-230.
[18]Ciocca V,Daskalakis C,Ciocca R M,et al. The significance of GATA3 expression in breast cancer: A 10-year follow-up study[J]. Human Pathology,2009,40(4):489-495.

相似文献/References:

[1]范春梅,许婉卿,史海鸿,等.Nicotiflorin对人乳腺癌MCF-7细胞增殖及凋亡的影响[J].福建医科大学学报,2013,47(06):345.
 FAN Chunmei,XU Wanqing,SHI Haihong,et al.Effect of Nicotiflorin in Inhibiting Proliferation and Inducing Apoptosis of Human Breast Cancer Cells MCF7[J].Journal of Fujian Medical University,2013,47(04):345.
[2]张志强,夏 笠,熊小文,等.灵芝三萜组分增强紫杉醇诱导HER2+乳腺癌细胞凋亡的研究[J].福建医科大学学报,2016,50(01):1.
 ZHANG Zhiqiang,XIA Li,XIONG Xiaowen,et al.Enhancement of Paclitaxel Induced Apoptosis in HER2+ BreastCancer Cells by the Triterpene Component of Ganoderma Lucidum[J].Journal of Fujian Medical University,2016,50(04):1.
[3]曾伟超,许建华,黄种心.A20在浸润性乳腺癌组织中的表达及其与临床病理特征和预后的关系[J].福建医科大学学报,2018,52(02):85.
 ZENG Weichao,XU Jianhua,HUANG Zhongxin.Expression of A20 in Invasive Breast Cancer and its Relationship with Clinicopathological Characteristics and Prognosis[J].Journal of Fujian Medical University,2018,52(04):85.

备注/Memo

备注/Memo:
收稿日期: 2019-07-09
基金项目: 泉州市科技计划项目(2016Z047,2018C045R)作者简介: 陈永强,男,住院医师,医学硕士 通讯作者: 许建华. Email:xujianhua63@163.com
更新日期/Last Update: 2020-10-15